Thank you, ladies and gentlemen, for standing by. Welcome to the Q1 2019 Earnings Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to our VP of Investor Relations, Kevin Hern. Please go ahead.

Thank you. Good morning. Thank you for joining us for Eli Lilly and Company’s Q1 2019 earnings call. I am Kevin Hern, Vice President of Investor Relations. Joining me on today’s call are Dave Ricks, Lilly’s Chairman and CEO; Josh Smiley, our Chief Financial Officer; Dr. Dan Skovronsky, President of Lilly Research Laboratories; Christi Shaw, President of Lilly Bio-Medicines; Anne White, President of Lilly Oncology; and Enrique Conterno, President of Lilly Diabetes and Lilly USA. We are also joined by Kim Macko and Mike Czapar of the Investor Relations team. During this conference call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide three and those outlined in our latest Forms 10-K and 10-Q filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, a reminder that our commentary will focus on non-GAAP financial measures, which exclude the financial contribution from Elanco during the first quarters of both 2018 and 2019, and present earnings per share as though the full disposition of the exchange offer was complete on January 1, 2018. We believe this view provides insights into the drivers of our underlying business performance as a dedicated pharmaceutical company and provides for cleaner comparisons to future and prior periods. Now, I will turn the call over to Dave for a summary of our progress in Q1.

Thanks, Kevin. The Company’s focus in 2019 is to execute on a broad and exciting range of new products and indication launches, to build and accelerate our pipeline, and continue to improve the focus and competitiveness of our company. We are pleased with the progress on these objectives in Q1 2019. First quarter revenue grew 5% in constant currency, despite a significant decline in U.S. Cialis revenue due to the recent loss of exclusivity. We made significant investments in key commercial and late-stage pipeline products and delivered non-GAAP EPS of 2% putting us on track to meet our full year financial guidance. Our key growth products, which all launched since 2014 contributed meaningfully to our performance and account for 39% of our revenue. While still relatively early in their product life cycles, these products continue to drive growth led by Trulicity, Taltz, Verzenio, and in collaboration with Boehringer Ingelheim, Jardiance and Basaglar. Total volume growth across the entire portfolio was 7% and excluding Cialis was nearly 13%. U.S. diabetes contributed strong volume growth of nearly 17%. Oncology growth accelerated in the U.S., Japan and China. And our international markets grew volume by 9%, as global launches of key brands continue across our major geographies. Excluding the impact of FX on international inventory sold, Q1 non-GAAP operating income as a percent of revenue decreased by nearly 600 basis points versus Q1 2018, reflecting a decrease in gross margin and investment in recent launches and multiple late-stage pipeline opportunities. On the same basis, operating income as a percent of revenue in Q1 increased by nearly 80 basis points versus Q4 2018, reflecting progress toward our 2019 full year margin goal of 28%. We exited Q1 on track with our plans for the full year. We have invested in our future growth, while delivering strong volume growth across the business. Importantly, several pipeline assets achieved milestones this quarter, including the regulatory submission for the Trulicity REWIND study for CV outcomes label in the U.S. and in Europe. The FDA granted priority review for Emgality for cluster headache in the U.S. The submission of Ultra Rapid Lispro for Type 1 and Type 2 diabetes in both Europe and Japan. The U.S. submission of our first connected device, our connected care prefilled insulin pen. And we had several Phase 3 data readouts. We also announced an updated timeline for expected regulatory action timing for nasal glucagon. We received notification. The FDA has extended the review timeline by up to three months to analyze information requested late in that review cycle. We remain confident in nasal glucagon submission package and look forward to FDA action in the coming months. In terms of capital deployment, we continue to utilize our strong operating cash flow to access value creating external innovation, which will enhance our future growth prospects. We completed the acquisition of Loxo Oncology and in key pipeline assets and expanding our presence into precision medicine. We completed the full separation of Elanco Animal Health via an exchange offer, retiring 65 million Lilly shares with approximately $8.2 billion. We entered into a global licensing and research collaboration with ImmuNext, focused on new medicines for autoimmune disease. We announced a global licensing and research collaboration with Avidity, focused on potential new medicines in immunology and select other indications. We announced an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, as well as a manufacturing facility to Eddingpharm, a Chinese-based specialty pharmaceutical company. And we returned an additional $3.5 billion to shareholders via a previously announced accelerated share repurchase program and $600 million in dividends, representing a 15% increase per share versus 2018. Moving on to slides five and six, you will see more details on key events since our February earnings call, including our announcement to introduce Insulin Lispro a low priced version of Humalog in the U.S. Now, I will turn the call over to Josh to review our Q1 results and to provide an update on our post Elanco financial guidance.

Thanks Dave. Slide seven summarizes our presentation of GAAP results and non-GAAP measures and slide eight provides a summary of our GAAP results. Looking at the non-GAAP measures on slide nine, you will see revenue increased 30%. Excluding the impact of FX on international inventories sold, gross margin as a percent of revenue was 80.2%, in line with our long-term goals for manufacturing efficiency and profitability. On the same basis, gross margin declined 130 basis points compared to Q1 2018, driven by production timing and lower volumes from post patent products. Total operating expense increased 12%, with marketing selling and administrative expense, increasing 13%, driven primarily by increased investment to support our recent launches, including DTC campaign campaigns to drive awareness from Emgality, Verzenio and Taltz. R&D expense increased 11%, reflecting the ramp up of multiple late-stage pipeline assets, the addition of the Loxo Oncology portfolio and the insight communicating to us that they would no longer co-fund the development of baricitinib, which reduces the royalty we will pay them moving forward. As a result of the investments described above, operating income decreased 8% compared to Q1 2018, which put our operating income as a percent of sales at 26.2% for the quarter. As our recent launches continue to drive revenue and operating leverage, we expect income growth and improvements in operating margin during the remainder of 2019. Other income and expense was income of $86 million this quarter compared to income of $70 million in Q1 2018, driven by over $100 million in gains of mark-to-market of public equities held through venture capital investments and strategic partnerships, partially offset by higher net interest expense. Our tax rate for the quarter was 12.9%, a decrease of 260 basis points compared with the same quarter last year, driven primarily by timing associated with the impact of U.S. Tax Reform. At the bottomline, net income declined 4%, while earnings per share increased 2%, due to a reduction in shares outstanding from share repurchases. Recall that our non-GAAP comparisons remove the 65 million shares retired through the Elanco exchange for both 2018 and 2019. While income declined this quarter versus Q1 2018 we made important progress on several fronts that will drive future growth, as demonstrated by growing revenue despite significant headwinds from the loss of exclusivity of Cialis in the U.S., investing behind key growth brands, such as Emgality, Verzenio, Taltz, Jardiance and Trulicity, and advancing several pipeline assets to the next phase of development, including multiple regulatory submissions. Slide 10 provides a reconciliation between reported and non-GAAP EPS and you will find additional details on these adjustments on slide 23. Moving to slide 11, let’s take a look at the effective price rate and volume on revenue growth. This quarter, foreign exchange reduced revenue growth by 2 percentage points. As Dave mentioned earlier, worldwide revenue grew 5% on a performance basis, driven by a 7% increase in volume, partially offset by price, Q1 is the ninth straight quarter our business grew volume in each major geography. U.S. revenue increased 3%. Like last quarter Trulicity, Taltz, Verzenio and Basaglar were the key drivers of 6% volume growth, partially offset by price. Excluding Cialis, volume grew nearly 15% in the U.S., highlighted by diabetes products delivering nearly 17% volume growth. Consistent with our 2019 financial guidance U.S. price declined 3%, driven by increased utilization of patient affordability programs, mainly for insulins and Taltaz, adjustments through estimates for rebates and discounts at higher contracted rates, primarily related to Trulicity, which were partially offset by favorable segment mix across the portfolio. Moving to Europe, strong volume growth of 9% was largely offset by the negative effect of foreign exchange and to a lesser extent price. Volume growth was led by Trulicity, Olumiant and Taltz. In Japan, strong volume growth of 7%, driven by Cymbalta, Verzenio and Trulicity, was largely offset by a drag of 6% from price, as a result of the government mandated price decreases that went into effect in 2018. Revenue in the rest of the world increased 9% on a performance basis this quarter, led by volume growth from Humalog, Trulicity, Cialis, Jardiance and the recently launched Tyvyt, a China-only anti-PD1 immunotherapy agent in collaboration with Innovent Biologics. As shown on slide 12, our key growth drivers were once again the engine of our worldwide volume growth. These products drove 14.8 percentage points of volume growth this quarter, an increase of over 100 basis points versus their contribution to growth in Q4 2018. Brands that have experience loss of exclusivity provided a drag of 530 basis points, driven primarily by Cialis. You may recall, the generic versions of the Cialis entered the U.S. market at the end of September last year, and as expected, we have seen a rapid erosion of sales. When excluding LOE, the rest of our products posted robust Q1 volume growth of nearly 16%. Slide 13 provides a view of our key growth products. In total, these brands generated nearly $2 billion in revenue this quarter, representing 39% of revenue. Trulicity continues to post robust growth, having achieved over 45% total share of the U.S. market, in a rapidly expanding class, that grew nearly 30% this quarter. Similarly, Jardiance posted impressive U.S. share gains in volume growth, now capturing 50% and 64% share of market in total and new prescriptions respective. Both products continue to be the market leaders in their classes. Emgality launch trajectory continues to be strong, with nearly 33% share of market for new prescriptions in the U.S., an increase of almost 13 share points from where we finished 2018. We expect increasingly strong performance in the U.S., combined with best-in-class access to drive meaningful sales contribution in the second half of 2019. Continuing with our non-GAAP explanations on Slide 14, foreign exchange rates had a modest impact on our revenue, but a more meaningful impact on cost of sales, due to the effect in last year’s quarter, resulting in the mid-single digit impact of operating income and EPS. Turning to our 2019 financial guidance on Slide 15, you will see that we maintained non-GAAP-pharma-only expectations we shared in February. And with the Elanco exchange offer complete, are now providing EPS on the same basis. Our non-GAAP earnings per share range is $5.60 to $5.70, an increase of $0.05 versus our previously issued guidance range, which included Elanco. While the line items remain unchanged from the previously communicated pharma-only expectations, I’d highlight two items that impact our outlook for the remainder of 2019. First, we will manage expenses to deliver within our SG&A range, while investing thoughtfully to drive continued revenue growth. And second in Q1, OID benefited from mark-to-market equity gains and our tax rate benefited from a net discrete item. We are maintaining our full year outlook for these items, however, as these items are highly variable and it is early in the year. Touching briefly on our updated GAAP guidance, we expect earnings per share to be in the range of $8.57 to $8.67, which includes a $3.7 billion gain on the disposition of Elanco recorded in discontinued operations. On Slide 16, we provide an update on our recent activity regarding capital allocation. Consistent with our strategic priorities, we spent over $8 billion on initiatives to drive future growth. In addition to investing in internal R&D, we closed the Loxo Oncology acquisition which augmented our pipeline, and returned over $4 billion of cash to shareholders. As Dave mentioned earlier, we completed the successful divestiture of Elanco this quarter via an exchange offer. We exited Elanco at an attractive price and recognized a $3.7 billion gain on the disposition. In addition, the exchange offer was substantially oversubscribed, and resulted in earnings accretion in 2019, from retiring Lilly shares. As we have returned to growth, our confidence in our business outlook has been reflected in meaningful dividend increases in 2018 and 2019. As we move ahead, our ability to continue to generate strong operating cash flow supports our pursuit of external innovation to enhance our long-term growth and create shareholder value. Now I will turn the call over to Dan to highlight our progress on R&D. Dr. Dan Skovronsky: Thanks Josh. Slide 17 shows select pipeline opportunities as of April 24. Movement since our last earnings call includes, the regulatory submission of Trulicity rewind data for CV outcomes label in the U.S. and Europe, submission of our Connected Care prefilled insulin pen for Type 1 and Type 2 diabetes in the U.S., submission of a fixed-dose combination of empagliflozin. linagliptin and metformin XR, for type-2 diabetes in the U.S. and submission of Ultra Rapid Lispro from type-1 and type-2 diabetes in Europe and Japan. We also highlight the initiation of Phase 2 testing for our IL-33 monoclonal antibody and immunology. The initiation of Phase 1 testing for three new molecular entities, including our GIP, GLP glucagon tri-agonist, and the attrition of two Phase 2 molecules. With the submission of Ultra Rapid Lispro, we are now on track to deliver 12 NME approvals since 2014. Therefore, a common question I get is, what’s next? As we replenish our late-stage pipeline, in the past 12 months we have made four big innovation bets with mirikizumab, pegilodecakin, our recently acquired RET inhibitor and tirzepatide. Moving to Slide 18, mirikizumab is our IL-23 in Phase 3 for psoriasis and ulcerative colitis, with expected data readouts in 2020 and 2021 respectively. We see first-in-class potential for ulcerative colitis, a disease with high unmet need in growing incidence, where we saw strong Phase 2 efficacy and clinical response and endoscopic healing. Based on positive Phase 2 data in Crohn’s disease, which we will be presenting in a few weeks at DDW, we are now moving quickly into Phase 3 for Crohn’s disease yet this year. Pegilodecakin is our first-in-class PEGylated IL-10 from ARMO Biosciences. We see strong biological rationale and single agent activity in renal cancer. There’s also an intriguing signal in combination with both chemotherapy and checkpoint inhibitors in several tumor types. We are looking forward to data readouts from the Cypress-1 and Cypress-2 non-small cell lung cancer studies by the end of this year, as well as the Phase 3 pancreatic cancer trial in 2020. We will also be starting a clinical program in renal cell carcinoma this year. Our most recent late stage entry is our potential first-in-class and best-in-class RET inhibitor from Loxo Oncology. Currently in the Phase 2 portion of the LIBRETTO-001 study, we look forward to having both additional data readout and a regulatory submission by the end of this year. This molecule has received breakthrough designation from the FDA for three indications, RET fusion positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion positive thyroid cancer. We are excited about the data we have seen to-date, which has shown robust response rates and encouraging response durations. We look forward to presenting new data at a medical meeting in the second half of this year. Finally, tirzepatide, our novel first-in-class and best-in-class GIP, GLP dual agonist twincretin, which started its Phase 3 SURPASS program in late 2018, on the heels of presenting impressive Phase 2 results in October at EASD. We believe tirzepatide could provide levels of efficacy not seen with existing products. All SURPASS studies for the global submission should start by the end of the year, with data expected in 2021. We also expect to initiate Phase 3 studies in obesity and a Phase 2 study in NASH later this year. We look forward to presenting new data at ADA in June on tirzepatide, including the additional dose escalation data from a Phase 2 trial in diabetes, data from a Japan clinical trial and new biomarker data from our Phase 2 trial supporting potential efficacy for NASH. We are excited about this cohort of innovative first-in-class, late-stage assets each with the potential to improve the standard of care across immunology, oncology and diabetes. We look forward to what’s next from these assets as they achieve important milestones and readouts over the next 12 months. Slide 19 shows a tally of a significant progress we have made since our last earnings call on key events we are monitoring for 2019 including submissions across four key line extensions or NMEs that I described earlier, the regulatory submission of Emgality for episodic cluster headache in Europe, positive results from CAROLINA CV outcome study of Trajenta, positive results for a Phase 3 study of Taltz for non-radiographic axial spondyloarthritis. Results from two Phase 3 studies of Tanezumab, the first in patients with chronic lower back pain and the second a long-term safety study in patients with osteoarthritis pain. Positive results from a Phase 3 study of Cyramza for first line EGFR non-small cell lung cancer. We also note that we received notification that for technical reasons the FDA has refused to file the supplemental NDA for Empagliflozin in type 1 diabetes and that we have made a decision to not pursue the development of Olumiant for psoriatic arthritis. In addition to the late-stage highlights I shared with you today, we are growing our early stage pipeline through both enhanced internal productivity and external innovation. We will highlight several examples in upcoming earnings calls. Now I will turn the call back over to Dave for some closing remarks.

Thanks, Dan. In the first quarter, we delivered strong volume based revenue growth of 5% on a constant currency basis, driven entirely by our key growth products. We made strategic investments in commercial and late-stage products, which will enhance our future growth prospects. We have seen good pipeline progress this quarter, including a number of regulatory submissions. In addition, we bolstered our early phase pipeline by advancing multiple assets into the clinic and signing research agreements. We also completed two significant transactions that will allow us to simultaneously focus the business and accelerate our pipeline of innovative medicines, the disposition of Elanco and the acquisition of Loxo Oncology. Finally, we returned over $4 billion to shareholders via the dividend and share repurchases. Speaking for the entire team at Lilly, we remain incredibly excited about the prospects in front of us to reach millions of people, who need better medicines for difficult diseases. And we are eager to continue to execute on the growth opportunity in front of the company. This concludes our prepared remarks and now I will turn the call over to Kevin to moderate our Q&A.

Thanks, Dave. We would like to take questions from as many callers as possible. So we ask that you limit your questions to two or to a single question with two parts. Karen [ph], please provide the instructions for the Q&A session. And then we are ready for the first caller.

[Operator Instructions] We will go to the line of Chris Schott from JPMorgan. Please go ahead.

The first one from me was just elaborating a little bit more on Trulicity dynamics this quarter, particularly as you think about price as well as to make sure I heard the comments in the prepared remarks properly. But how should we be thinking about net pricing and the overall pricing environment for Trulicity in 2019? And were there any one-time impacts or true-ups of rebates for Trulicity this quarter? My second question is really quick one on Emgality, and just how we should we be thinking about where net pricing is going to shake out for this one. And should we think about second quarter results reflecting maybe more normalized gross to net then we saw with the Q1 result? Thanks very much.

Thanks, Chris we will go to Enrique for Trulicity and then Christi for Emgality.

Chris, thank you for your question allow me to provide some color on Trulicity’s overall performance. We continue to be very excited about the underlying business fundamentals of the product. When we look at volume growth, we are basically the beneficiary of very strong share growth. We are now sitting at 46%, which is an all time high for Trulicity and with the tailwind of very significant class growth now sitting at 30%. Something to note is that when we look at sequentially volume while scripts basically increased for Trulicity from Q4 of 2018 to Q1 of 2019 by about 5%/6%, our actual shipments declined by 7%. So I want to make sure that we are looking at the underlying business fundamentals and not necessarily just some shift in retail or wholesale inventory dynamics. When it comes to pricing, there hasn’t been a step change, when it comes to pricing. I think of course, we see pricing pressures across all diabetes categories. But it’s important to note that our price this quarter was comparable to our price in Q4 of 2018. Now what we basically see in terms of pricing is relative to Q1 of 2018 is higher rates, when it comes to managed care and rebates. Growth in highly rebated segments, whether it’s the Department of Defense,VA and so forth. And then we also had a negative impact due to changes in the estimates for rebates and discounts.

And Chris on Emgality, your question on net pricing and will be more normalized on Q2, what we saw in Q1, first of all, on-demand, very excited about the fact that we are now the number two CGRP passing a JV in both new prescriptions and total prescriptions. And we are on track in Q2 to pass Aimovig in new prescriptions. As we look at the net, we saw a higher than typical free goods as reimbursement was coming on. To give you a little bit of flavor the first quarter had a 57% of commercial claims were reimbursed. We exited Q1 at 67 or two out of every three prescriptions are claims -- commercial claims being reimbursed. So as the reimbursement comes on in Q2, we should see an improvement in that.

Next we will go to the line of Jason Gerberry, Bank of America. Please go ahead.

Christi, just to follow up on the Emgality comment I know that a lot of companies in the space of kind of frame second half payer environment is a little bit fluid. So is your comment that where you exited 1Q, should we be thinking about that as a linear trend. Are there any puts and takes going on changes in the reimbursement of CGRP biologics just wanted to get a better sense there. And I guess my follow up probably staying with you AbbVie’s SKYRIZI got pretty good early access. And so I am just sort of curious, your thoughts winners and losers there either be the established novel interleukins or do you see this as more cannibalization of AbbVie’s own Humira franchise. Thanks.

Sure so, continuing on Emgality in terms of access. First of all, we saw very good receptivity by the payers for this class really given doctors and patients choice. And also not having many if any real restrictions for primary care prescribing. So on the reimbursement side we see the payers coming on board and more and more are coming on board right now our access ending Q1 is 82%. So we do expect that to get better and better over the course of the year. So I hope that answers your question there. On SKYRIZI, the data on SKYRIZI is as expected and as we look at tolerability to compete, the competitive landscape that we environment that we are in really doesn’t change access is very similar SKYRIZI and Taltz all of the newer agents really coming to market and helped increase the expectations of patients and doctors should have on really skin clearance. And so it’s a competitive marketplace, but we like our chances because with Taltz in the dermatology office we know clear skin, very fast and it lasts up to five years, we have seen data that sustained and no new safety signals. And we also have the head to head versus an IL-23 that will be coming out this year which will demonstrate that speed and clearance at 12 weeks and 24 weeks for the IL-23 really show their peak efficacy. So we are looking forward to that and in rheumatology we will continue to compete there as we just released our head-to-head data versus Humira showing superiority and then later this year, being able to look at the regulatory approval of AxSpA. So the competition is fierce, but our chances and our add with Taltz are extremely good. And we don’t care huge difference in the landscape because of really coming in.

Seamus Fernandez from Guggenheim. Please go ahead. I am sorry. One moment. Yes go ahead please.

So just a couple of quick questions. As we think about the evolving competitive landscape in the insulin space. We have seen Humalogtake up quite a bit of share in a short period of time. And then there’s also the threat of potential biosimilars reaching the market in the next couple of years. The evolving landscape and how that potentially impacts your portfolio as it relates to Humalog or also for the long-acting insulins going forward. And then just a second quick question for Dan. You guys have some data on your ERK inhibitor at ASCO, just hoping that you could give us your thoughts on data coming at ASCO for that product and perhaps any other datasets, that you think we should be watching for. Thanks.

Thank you, Enrique, if you want to answer the insulin question we will go to Dan.

Sure. Clearly, there’s -- there are new competitors in the insulin space, I think, in the case of EADVI think it’s important to reflect that their most of their share gains really have been driven and managed Medicaid outside more look and Humalog of management are -- our overall script are basically flat, clearly there is an evolving landscape, when . it comes to insulin with the potential entry of other insulins follow-ons. As you know the insulin categories are going to be transitioning to BLAs in the 2020 timeframe. Clearly, there’s questions about interchangeability and when is that going to play out as we said in the past, we don’t view interchangeability or something imminent. We eventually think, this is going to happen, but it needs to be more clarity. So this is likely something that won’t happen before 2021. Now, it’s difficult for us to predict when insulin follows up will come into the market in particular in the U.S., given that some of these products have expressed certain expectation when it come to launch timelines, but have been delayed. Importantly, to note as well is that we continue to evolve our overall instrument strategy and we like to say that we are reimagining insulin systems and an insulin delivery with by basically bringing in a connected care platforms to be able to improve patient outcomes in a much more meaningful way. So we are excited about our overall innovations with systems connected care, but also bringing new insulin like our Ultra Rapid Insulin Lispro that we are developing. Dr. Dan Skovronsky: Yes, thanks for the question on our ERK inhibitor. This is a Phase 1 program, but it’s still very early, but we are pretty excited about it. The reason that we are excited about this pathway is because the MAP Kinase pathway is implicated in driving about 30% of solid tumors. So it’s a great opportunity to drive that pathway. At ASCO, we have a couple of presentations on the ERK inhibitor, including some of the early Phase 1 data in a variety of patients and some data in lung cancer patients as well. So we look forward to being able to share that, but again it’s a early program. I think we have a few other disclosures ASCO, but we are excited about, turn it over to Anne to comment on late-phase disclosure.

Yes. So one of the disclosure that we are very excited about at ASCO is the results of our EGFR mutation positive first-line lung cancer study in CYRAMZA. So this is the RELAY Study and we shares top line data in March that the study was positive and met the primary endpoint of progression-free survival. So we will be submitting to regulators globally midyear and approval on this would make the six indication that we have achieved for Cyramza. Importantly, we are excited about the data and we look forward to this oral presentation at ASCO. Also there’s currently the standard of care in this setting and we know that our magnitude of benefit must be competitive with that. We look forward to providing more answers for patients in the setting and also providing more options for physicians as they look to sequence therapy for the best outcomes for their patients. So we look forward to sharing more with you at ASCO.

And next we will go to Tim Anderson with Wolfe. Please go ahead.

On the rewind data for Trulicity coming up at ADA without running the data. Can you just talk about your level of excitement and if this is the data where once just presented you think the prescriber community is going to say well, that’s really a game changer? And then second question on Tanezumab, I think a lot of investors see this program is probably dead based on the latest data disclosure from you and Pfizer. Can you just share your perspective?

So we will go to Enrique on rewind, and then Dan, you want to talk about the tanezumab results.

Yes. We continue to be excited about the rewind results for Trulicity. I am going to -- I have a plug here for my Investor Relations colleagues that we have an investor, we are planning on in new investor call at the ADA post disclosure of rewind we saw. Also, we hope to either see you there. Hope there you can either connector be there in person. Dr. Dan Skovronsky: Yes. Great, thanks for the question on tanezumab. Before I address your question on the future tanezumab, I think it’s important to comment on why we entered into this partnership with Pfizer and why we have pursued this program. It’s obviously because of the dramatic unmet medical need here. There are nearly 60 million Americans suffering with chronic pain from osteoarthritis and chronic lower back pain, many of whom have moderate to severe disease and aren’t getting relief from currently available therapies. When you put that in the context of the drawbacks of the therapies that are currently available, including in many cases opioids, you can just understand how important it is to have new non-opioid mechanisms to address pain. So that’s why we entered into this program and as we said before, we entered in, with a high level of confidence on the efficacy of this mechanism. But what we saw to discharge was the safety risk through this program. And so that brings us to the final study, which of course was designed to fully understand the safety risk of this mechanism that reason in the study enrolled a different population of patients and we enrolled in the others, we wanted to compare to NSAIDs and therefore we had to enroll patients, who were getting some measure of relief and it is tolerate chronic NSAIDs. So we are continuing to analyze the results from that study from 10.58, we are looking at that so in the context of all of the available data on tanezumab. Our plan then is to discuss the totality of the data with regulators in the coming months and that will help us decide on what the next steps are, and then we will be able to share an update with you when that’s globally.

Next we will go to the line of Geoff Meacham from Barclays. Please go ahead.

For Dan on the Olumiant and atopic derm, what do you guys see as differentiation in the data so far among the JAKs. I know you still have some data coming up. And in this indication is your view from the field how attractive oral options are versus injectables. And then just a real quick one for Enrique on Trulicity, just wanted to ask your view of the class growth differences in the U.S. versus O-US and how durable says, I know this has been a big driver in independent of the share gains that Trulicity has gotten over the years. Thank you.

Thanks, Geoff. So Dan and then we will go to Christi. Dr. Dan Skovronsky: Okay, maybe I will start with the comment on differentiation and toss it to Christi for the commercial insights on patient interest and in an oral here. Although I should just say it’s premature to speculate differentiation versus other molecules where we haven’t seen the full data from theirs or even ours. But we are excited about the opportunity to be first year in atopic derm. Christi?

Yes, exactly, right now DUPIXENT is available, but it’s an injectable for the more severe type of atopic derm and there’s so many more patients out there suffering millions of patients. In fact, our dermatologist tell us atopic derm space reminds them of the psoriasis space about 15, 20 years ago. So we do think it’s a large opportunity and we do plan to be the first JAKs to market. We have released on the fact that our first two studies were positive. You probably saw that we have three more studies to read out this year and then based on the totality of that data, if they continue to be positive. We will be submitting next year.

So when it comes to Trulicity class or GLP-1class growth, I think we see the same dynamics in most markets, the drivers are similar, which is the updated guidelines that having recently released. So when we look outside of the U.S., we are GLP-1class growth is in the mid ‘20s, given the maturity of the class in the U.S., it is impressive that the growth in the U.S. is even higher than that, but it’s very exciting to see and as a corollary to that, I think the Trulicity’s performance is very consistent across many markets.

Next we will go to the line of Andrew Baum from Citi. Please go ahead.

Just going back to SKYRIZI for the first question. What’s your first-line market share for Taltzin psoriasis and do you expect to be able to grow it now that’s SKYRIZI has been introduced into the market. I am obviously referencing Avi’s enormous rebates influence as well as the profile of that drug and what it may mean for the contraction of the more refractory lines of therapy? And then second, perhaps Dave could comment on the timing and the impact of the proposed rebate reform on your diabetes business expressly on the near-term impact for realized pricing because of the Medicare math, assuming it does get implemented at the beginning of next year. Many thanks.

Thanks, Andrew, so we will go to Christi for the comment on SKYRIZI and then, Enrique, if you want to talk about the impact on diabetes so then proposed rebate Safe Harbor world.

Yes, so in dermatology specifically, our total prescriptions are a little over 15% and we do see growth continuing absolutely, we see actually with the new therapies that have come to market. It actually has increased the market growth, so right now the market is growing at 13%. And the more of the newer agents coming to market, I think the more, you will see the older TNFs be used for short periods of time or potentially not used first line in the future. And so we do see our growth coming from the fact also our ability to compete in dermatology. So the SKYRIZI versus Taltztop to head will be another place for us to go five year data sustained efficacy and we really are the only one that’s had been able to show not only clear positive 100, but the ability to do it fast and one to two weeks and that sustainability. So our growth continues and we continue to see have very high confidence that growth will continue.

The biggest impact from the proposed rule is really at the patient level, because patients will have access to medicine side to more affordable prices. And if you take that threat forward, I think what you will basically see is better appearance, and I think that’s something that we all want when it comes to healthcare, which is better appearance to medicine. So the impact that is not often talked about is really, when it comes to maybe an impact on volume. When it comes to some of the mechanics and so forth honestly, I view pretty neutral overall.

Let me just jump in Andrew, on both of those points. I think it’s important to note in psoriasis two things, one that there’s four stepping through TNFs for almost every patient, if that were to change, I think that’s a big positive for the newer innovation, so the doctors can select appropriate therapy for patients with psoriasis noting that TNFs don’t work nearly as well as in the new classes and amongst those we think tells us the best profile. Also within derm, there’s a lot of switching anyway, so the front-line market is versus the total is much smaller than other immunology indications. That’s an important thing to keep in mind. On the rebate rule we do, we are planning for implementation January 1, I think Enrique rightly notes that the volume upside, the thing I would worry about is rate compression because presumably you would have more facial transparent pricing. But I think across our portfolios, because of the hike consolidation on the payer side, the rates are pretty compressed already. There aren’t big differences between what the payers are paying. So that’s why we lean into this one, we think it’s the right policy answer to help seniors with medication costs and to shift the debate from list pricing to net pricing, which we see as our long-term interests.

Thanks for your questions, Andrew, next caller please.

I will go to Vamil Divan from Credit Suisse. Please go ahead.

Hi. Great. Thanks for taking the questions. So just first on Olumiant, I think, I asked this question before, but just the U.S. opportunity there against our limited sales this quarter. I think you said in your prepared remarks, you are not going to be filing for psoriatic arthritis, just correct me if I miss heard that? And I am just, I guess, on how you think about getting the 4-milligram to the market and so the opportunity in the U.S. for that product and also the implications from the data of Pfizer recently released from their long-term trial showing some additional question on thrombosis? And then the second one, just following up on the psoriasis questions, you mentioned mirikizumab and the data there in psoriasis, I know you said you will be first in GI, I am just curious what the differentiation of any would be in psoriasis for that product or is it really more just a GI focus we should think about? Thanks.

Thanks, Vamil. We will go to Christi for Olumiant Americas questions.

Okay. So for Olumiant, yeah, I think, what we see in the U.S. is it will be slow and steady in Olumiant 2 milligrams RA. Your question about psoriatic arthritis, you did hear correctly, as we look at the opportunities for us to be best-in-class, first-in-class and really enter market with unmet need. In psoriatic arthritis in the ankylosing spondylitis non-radiographic expire as well. We already have Taltz and Taltz has shown very remarkable results and so we feel very good with that play as we look to study Olumiant and other indications like atopic dermatitis. Remember Lupus got Fast Track designation in December. We are studying both 2 milligrams and 4 milligrams in that indication, as well as atopic dermatitis and we have our alopecia areata study where Phase 2 will readout later this year and if positive we will move to Phase 3. So we are still very big on the opportunity of baricitinib as a whole, the RA 2 milligrams will be slow and steady growth and 4-milligram is being studied and we looked at CD efficacy results there and bring it to market if they are positive. In regards to the Pfizer question about what readout in their Jack high dose. So we -- as we look at the data that we have and 55 countries that have approved Olumiant, we haven’t seen unusual safety signals in DTEs and we continue to study, obviously, post marketing research that we are doing in collaboration with agreement with FDA both on real world evidence and in randomized clinical trials, those will continue as well. So no news on -- no unusual news on our Taltz and Olumiant like the Pfizer announcement. And then lastly on mirikizumab, so, yes, we are in Phase 3 studies with both psoriasis and ulcerative colitis, we are very excited about the GI space because mirikizumab should be the first IL-23 to ulcerative colitis. We also finished our Phase 2 data on Crohn’s disease that data will be released at DDW in just a few weeks here in May. So look for that. And then, yes, in psoriasis we are doing a Phase 3 clinical trial with some competitive endpoints in head-to-head data. So when that study reads out we will be looking to see if we can have stronger and more sustained results then current IL-23 in the market.

Vamil, thanks for your questions. Next caller please.

And next we will go to Umer Raffat from Evercore. Please go ahead.

Hi. Thanks so much for taking my questions. First, can you quantify for us what percentage of TRx are paid versus free on Taltz, as well as Emgality? And secondly, I noticed one of the trials reading out for you this fall, the IL-10 plus Opdivo trial in second-line lung has been shrunk from 100 down to 50 patients. Is that simply a function of increasing Keytruda use in first-line or is there another dynamic here as well? Thank you very much.

Okay. Thank you. We will go to Christi for the questions around Taltz and Emgality and then Enrique will talk about pegilodecakin.

Sure. First of all, Lilly believes in really open access and giving choice to patients and physicians. So we continue to work with payers on access with Taltz. In spite of that, we -- the barriers that we have had -- we had very good uptake with Taltz and as we look at our programs, patient specific, copay cards, et cetera, being able to allow patients on drug and then transition to insurance coverage, we see that two-thirds of patients in the market on Taltz are paid for. On Emgality, as I said before, the commercial claims that have been submitted, we see in Q1 that 57% of those have been reimbursed. And as we exited Q1, we saw that in the mid ‘60s, two out of every three patients that submitted a claim we had reimburse coverage for.

Thanks, Christi.

Yes. On the question on pegilodecakin, this is the Cyprus 2 study referring to. So this is a second-line lung study, its Phase II study IO-naive patients. So following first-line treatment, but not in immunotherapy and then it’s in combination with Opdivo in low expressers. And what we are finding, as you know, well, is that IO-naive patients in the second-line are becoming increasingly rare. So what we decided to do was analyze that data and have that inform the next steps for the program. But not continued to further enrolled patients in this somewhat diminishing population. We have remain confident that the greatest opportunities for pegilodecakin remain in lung cancer, both in the first-line setting and in later lines, and also in renal cell cancer. So as Dan mentioned, we will be starting a renal cell study later this year. But we look forward to readouts in lung at the end of this year and then also in pancreatic cancer early next year and remain confident in the opportunities for pegilodecakin across those tumor types. So I look forward to hearing more towards the end of the year, both on Cyprus 2 and on the Cyprus 1 study, which is in the first-line setting.

Thanks, for the questions Umer. Next caller, please.

And we will go to David Risinger, Morgan Stanley. Please go ahead.

Yes. Thanks very much. I have two questions. The first is for Dave. I am hoping that you can help us understand a little bit better, how you are thinking about the forthcoming HHS action on the elimination of rebates and how that will negatively impact companies that use volume based discounts such that a product like Taltz will be able to step up on the formulary and maybe move into a formulary position that another larger player held in psoriasis? And then second, Enrique, with respect to Trulicity, just hoping that you can help us with a little bit more of a bridge. So you said that, Rx increased sequentially by 5% to 6%, actual shipments declined by 7%. So does that mean there was an inventory work down of 12% to 13% and could you also quantify the negative dollar change in reserves? Thank you.

Thank you, Dave, and then Enrique.

Yes. Thanks, Dave. So on the rebate rule, again, we are planning for this January 1, of course, it’s Part D, there are some legislative efforts to look at regulating commercial market. I guess, at this point, my speculation would be that looks more challenging either for political or practical reasons. But I do think once Part D changes and I think we are, as I said, planning toward that, you will start to see increased interest from payers that are not in the government systems or commercial payers to have similar benefits provided to their beneficiaries, particularly in chronic disease where list price effects have a lot of distortion and increased out-of-pocket costs and we have all heard the upgrade around that really centered on insulin, frankly. So I think your logic is the right one in the sense that today with rebates which are not share with patients and confidential payers have a strong incentive to keep those confidential and use those to compete on premiums, that’s the way it works. I think in the future world where that can’t be the way they use those rebates, they will need compete for premiums in other ways, efficiency, presumably, and patients will have a choice at the counter based on net pricing. I would assume the doctors are informed about those net prices and that also becomes an influence on prescribing. So for new innovative therapies hypothetically one in specialty market or in a general practitioner market like Emgality, I think that will be an important part of any company’s strategy to understand the net price that will officially be there for the consumer. The final comment is, of course, Part D is senior program. So the demographics will affect us mostly in our diabetes franchise initially and that’s where a lot of our planning is focused right now.

Thanks, Dave. Enrique?

Whenever we look at sequential growth you -- there’s a lot -- what I call the colloquially a double whammy effect. So we could be double counting here is not to simply add up. One good way to think about it is just if we were to shift 5% of the units from Q4 to Q1 that that explains 10 percentage points of difference, but in reality we are only shipping 5% of units from one quarter to another. That’s a long way of saying that, I will have your estimate likely the -- we don’t have full visibility into the retail inventories, but my assessment is about 6 points.

Thank you.

Dave, thanks for the questions. Next caller please.

And next we will go to Steve Scala from Cowen. Please go ahead.

Thank you. I have a couple of questions. We were expecting Verzenio data in 2019 from MONARC Her and MONARCH plus. I am wondering if there still on track. And then, secondly, Enrique, one of the concerns with the upcoming rewind readout is that the benefit might be driven by the 30% or so of patients in the trial with pre-existing cardiovascular disease and that the remaining patients add little to the overall outcome. So, overall, the benefit might be a solid but unspectacular 20% or so reduction in risk, which won’t offer opportunity for differentiation. I am just wondering, can you tell us not to be concerned about this point? Thank you.

All right. We will go to Anne for the question on Verzenio and then Enrique on rewind.

Yeah. So you are correct. So we are looking to deliver our new data to drive additional growth in one of them the HER-2 positive study, which we will report results on towards the end of the year at a medical meeting. The MONARCH 2 overall survival data will readout as we had communicated in the past in 2020. And then we also have importantly the adjuvant study reading out in 2021. And I appreciate asking about Verzenio because there has been an encouraging start to the year. The revenue grew 30% over Q4 and we also are seeing nice uptake across Japan and European markets. So we look forward to these additional data readouts helping contribute to that message. But look forward to those readouts coming as we had communicated in the past.

Thanks, Anne. Enrique?

We are unable to provide additional comments on rewind, but look -- we look forward to seeing you at the conference call.

Thanks, Steve. Next caller, please.

Thank you. Next we will go to the line of Alex Arfaei, BMO. Please go ahead.

Okay. Thank you and good morning. On tirzepatide, your -- good to see the program formally, I guess, extended in obesity and NASH. Regarding your Phase 3 obesity trial, could you give us a little bit more color in terms of the outcomes you are looking forward the competitor are you using and the potential readout? And you mentioned you have dose titration data at ADA, can you comment on the extent to which that data shift you dosing for the Phase 3 trials, particularly the high dose? Thank you.

Enrique?

Yeah. So we are very excited about the tirzepatide and being able to start our Phase 3 Type 2 diabetes study and basically pursuing both obesity in Phase 3 and NASH in Phase 2. We are not providing additional color on the specific obesity trials that we are conducting -- that we plan to conduct. Clearly we need to have the appropriate discussions with the FDA as we engage in this Phase 3 trial, but we plan to do sometime -- that sometime in the future. And as far as the titration question, yes, we do plan to have presentation at ADA, looking at some of the additional titration data for separate thing.

Thanks for the questions, Alex. Next caller, please.

Thank you. Next we will go to Louise Chen, Cantor. Please go ahead.

Hi. Thanks for taking my questions. So my first question is on mirikizumab, you had mentioned that you will likely be the first to IL-23 to marketing you see in Crohn. I am just curious in addition to that, what are the competitive advantages do you see as it relates to other ILs and about and also Jack? And then the second question I had was on LOXO-292, you showed very good ORR median duration percentage of patients on therapy. How do you think that will hold up into the Phase 2 readout and how do you think you might compare with other RET inhibitors in development? Thank you.

Thanks. We will go to Christi for mirikizumab and then Anne on RET inhibitor.

Thanks Louise for the question on miri. So, to be clear, we expect to be first in to the market on ulcerative colitis and first of a couple to market on Crohn’s disease. So, you never know, we have been speeding up the Phase 2 trial and look forward to entering the next, but that’s where we are on GI. We are very excited, because our studies are set up to be best-in-class and so if they read out positively, we expect to not only be first-in-class or best-in-class in ulcerative colitis and Crohn’s disease.

Thanks, Christi. Anne?

Yes. When we have thoughts on the Loxo question, when we start to move into precision medicine and to obtain a RET inhibitor, we really thoroughly survey the landscape and selected the molecule in the portfolio that we believe to be first and best-in-class, and we continue to believe that today. We intend to submit in the U.S. by the end of the year end in Europe shortly thereafter. So to answer your question, we remain very confident in the efficacy, safety profile and the duration of our RET inhibitor. And we will continue to expect that will deliver first in both lung and thyroid cancer. So we are actually be having -- we are presenting an update on the registrational data in the second half of 2019 at a major -- a couple of major medical meetings in advance of that potential regulatory filing. And importantly, as you look at this data set, we now have over 400 patients enrolled across tumor types with RET fusion or mutations. And so we fully expect the data to continue to bear out what we saw last year, which is in response rates, as you said, from 60% to 80%, with well over 90% of patients remaining on study. This is the data reported last year and then we will provide an update later this year.

Thanks, Anne. Louise, thanks for your questions. Next caller, please.

Certainly. [Operator Instructions] Next we will go to Navin Jacob from UBS. Please go ahead.

Hi. Thanks for taking my questions. So, number one, I just wanted to -- I am sorry to beat a dead horse on GLP-1 pricing. But Enrique, if you could just dig in a little bit further, just wanted to understand in Q1 of this year, how much of the lower price was related to Medicare Part D on whole changes versus other rebate related changes, because you mentioned that there was rebate estimate adjustments, I want to understand is that a one-time impact for accrual accounting related issues or is it something that we should be thinking about as continuing on going forward. And so, overall, just wanted to understand, where is the GLP class going in terms of pricing, is there going to be continued pricing pressure over the next couple of years? And then, secondly, just on op margins, if you could help us understand longer term where the op margin profile for the human health business will look like. Can we expect margins to reach mid-to-high ‘30s in line with some of your other peers? Appreciate the help.

Thanks, Navin. We will go to Enrique for Trulicity. Then Josh on the op margin question.

Yeah. So I just first to address the question about the doughnut hole. The doughnut hole becomes a little more important in Q2, I don’t have the numbers in front of me, but in the case of diabetes medicines maybe Q1 is maybe only about 10% of the overall doughnut hole from an accounting perspective, what we are going to see throughout the year. So when we think about Trulicity, while there was some impact of the doughnut hole. It was not material to the pricing results. As we -- as I mentioned, when we look at Trulicity, we do have high rebates in managed care and so forth relative to Q1 of last year, the change is due to estimates -- change in estimates for rebates and discounts. That -- yes, that is basically changing because of how we had accrued them based on a full review of the claim that we received later basically changes the information that we have on hand and we need to account for that as soon as we know that information. So, yes, that is a particular impact that was from other quarters that basically is impacting this particular quarter. So that’s probably as much detail as I can provide.

Thanks, Enrique. Josh?

I mean on operating margins for the quarter, we were slightly above 26%, our guidance for the year is to be at 28% we are confident we will get there. I think you will see through the remainder of the year that we will see if power guidance topline growth netting out currency effects similar to what we are seeing this quarter and we will see sort of the operating expenses at a more constant absolute level than what we are seeing in Q1. So we are confident in our 28% for the year. And then for 2020 our goal is 31% and we are confident as well in achieving that. That’s for pharma only, so that’s on our new basis excluding Elanco. We see good opportunity to get to the 31%. So we are no change there. I think if you look past 2020, we would expect margin expansion to continue. We have a limited patent expirations in the first half of the next decade and we still have the new products that we are launching now will still be in their growth phase. So we definitely see margin expansion opportunities post 2020. But we haven’t given a specific goal.

Thanks, Josh. Next caller, please.

There are no further questions in queue at this time. Dave Ricks, please go ahead.

All right. Thank you. Thank you all for joining us and we appreciate your participation in today’s earnings call and your interest in the Eli Lilly and Company. We began 2018 with a lot of momentum and we made meaningful progress in our first quarter. Although, Q1 was a period of investment, we remain committed to our revenue and profitability goals for 2019 and 2020. We continue to advance our innovation-based strategy to progressing internally discovered medicines, augmented with external innovation. We completed two transformative transactions this quarter as well, with the full separation of Elanco and the addition of Loxo Oncology. With a robust pipeline and volume driven revenue growth Lilly continues to be a compelling investment. Thanks again for dialing in. Please follow up with our IR team if you have additional questions that were not addressed on today’s call. Have a great day.

Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive Teleconference. You may now disconnect.